secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001193125-22-284535
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences Q3 net loss narrows to $0.18/sh; cash $44M; appoints Scott Brun to board
--------------------------------------------------------------------------------

- Q3 2022 net loss $3.4M ($0.18/share) vs $7.8M ($0.54) in Q3 2021; R&D expenses fell to $1.4M.
- Cash and equivalents $44.0M at Sept 30, 2022; 21.0M shares outstanding; no revenue.
- Lead candidate FB-102 on track for clinic late 2023/early 2024; addressable market >$6B.
- Appointed Scott Brun, M.D. to Board (effective Nov 10); ex-Head of AbbVie Ventures and Product Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522284535/0001193125-22-284535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522284535/d419341d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-284535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer